FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVIB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response.	0.5					

longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person * Benton Andrew				2. Issuer Name and Ticker or Trading Symbol Ensysce Biosciences, Inc. [ENSC]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
C/O ENS	(Last) (First) (Middle) C/O ENSYSCE BIOSCIENCES, INC., 7946 VANHOE AVENUE, SUITE 201				3. Date of Earliest Transaction (Month/Day/Year) 06/23/2022							Officer (give	e title below)	Othe	r (specify below	v)
(Street) LA JOLLA, CA 92037				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ I	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City	y)	(State)	(Zip)			T	able I	- Non-Der	ivative S	ecuritie	s Acquired,	Disposed	of, or Bene	ficially Owner	d	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			2A. Deemed Execution Dat any (Month/Day/Y		Date, if	Code (Instr.	8)	4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		Of (D) Own Tran (Inst	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		d (Ownership Form: Direct (D) or Indirect I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				1			Coc	de V	Amount	(D)	Price			[(Instr. 4)	
			Table II -					in this displa	form are	e not re rently v or Bene	equired to valid OMB ficially Own	respond control n	unless the	tion contain e form	eu sec i	474 (9-02)
	e Conversion Date Execution or Exercise (Month/Day/Year)		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code		5. Number of Derivative Securities (N			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		9. Number o Derivative Securities Beneficially Owned Following Reported Transaction(Ownersh Form of Derivativ Security: Direct (D or Indirects)	Beneficia Ownershi (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expira Date	ition	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock	\$ 0.425	06/23/2022		A		15,000		(1)	06/23	1/2032	Common	15,000	(1)	100,850	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Benton Andrew C/O ENSYSCE BIOSCIENCES, INC. 7946 IVANHOE AVENUE, SUITE 201 LA JOLLA, CA 92037	X						

Signatures

/s/ Andrew Benton	06/27/2022
***Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On June 23, 2022, Mr. Benton was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value \$0.0001 (1) per share, with a per share exercise price of \$0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.